血小板添加剂溶液和病原体减少对输血安全,患者管理和血小板供应的影响
Georges Andreu1, Karim Boudjedir1, Nicolas Meyer2
1French National Agency for Medicines and Health Products Safety (ANSM), Saint Denis, France.
Transfusion medicine reviews
|February 7, 2025
概括
与血相比,血小板添加剂溶液 (PAS) 和病原体减少技术 (PR) 显著降低了不良输血反应 (ATR). 病原体减少技术表明,细菌传播减少了95%,提高了血液安全.
科学领域:
- 输血医学 输血医学
- 血液学 血液学 血液学
- 公共卫生 公共卫生
背景情况:
- 自1998年以来,血小板缩 (PCs) 在法国已经成为标准.
- 血小板添加剂溶液 (PAS) 和病原体减少技术 (PR) 已越来越多地实施.
- 在2007年至2021年期间,皮衍生PC (BCPC) 的使用率从23%上升到70%.
研究的目的:
- 评估PAS和PR对输血不良反应 (ATR) 的影响.
- 评估患者管理和输血组织的变化.
- 为了比较表衍生PCs (APCs) 和BCPCs之间的ATR发生率.
主要方法:
- 2007年至2021年法国输血数据的回顾性分析.
- 在不同的PC处理方法 (血,PAS,PR) 中,ATR发生率的比较.
- 对ATR类型的分析,包括细菌传播和合免疫.
主要成果:
- 帕斯和PR-PCs的ATR总体发病率低于等离子PCs (PL).
- PR-PCs显著减少了95%的输血传播细菌感染 (TTBI).
- 与BCPC相比,APC对过敏,TTBI和非免疫接种的ATR率更高.
结论:
- 通过减少ATRs,PAS和PR技术提高了血液安全.
- 病原体减少技术在预防细菌传播方面非常有效.
- 虽然PR-PCs具有较低的血小板含量,但它们有助于减少每个PC的ATR总发病率.
更多相关视频
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
461
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
461
Formation of the Platelet Plug
3.9K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
3.9K
Blood Transfusion and Agglutination
10.7K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
10.7K
Structure and Function of Platelets
959
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
959


